Avinger Inc (OQ:AVGR)
Business Focus: Medical Imaging Systems
Mar 20, 2024 04:05 pm ET
Avinger Reports Fourth Quarter and Full Year 2023 Results
New Strategic Partnership Provides Funding to Support U.S. Growth Initiatives and Coronary Product Development, Opens New Pathway for Sales in Asia
Mar 12, 2024 09:00 am ET
Avinger to Announce Full Year 2023 Results on March 20, 2024
REDWOOD CITY, CA / ACCESSWIRE / March 12, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the fourth quarter and full year 2023 after the close of trading on Wednesday, March 20, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
Mar 06, 2024 07:30 pm ET
Avinger Announces Strategic Partnership and up to $15 Million Equity Funding Agreement with Zylox-Tonbridge
Initial $7.5 Million Strategic Investment
Feb 13, 2024 08:31 am ET
Thinking about buying stock in Avinger, Cloudflare, Backblaze, Shattuck Labs, or Beamr Imaging?
NEW YORK, Feb. 13, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVGR, NET, BLZE, STTK, and BMR.
Oct 26, 2023 04:01 pm ET
Avinger Reports Third Quarter 2023 Results
REDWOOD CITY, CA / ACCESSWIRE / October 26, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2023.
Oct 19, 2023 08:00 am ET
Avinger to Announce Third Quarter 2023 Results on October 26
REDWOOD CITY, CA / ACCESSWIRE / October 19, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2023 after the close of trading on Thursday, October 26, 2023. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
Sep 27, 2023 08:00 am ET
Avinger Raises $5.3 Million via At-The-Market Facility
Strengthens Balance Sheet in Support of Tigereye ST Launch and Coronary Product Development
Sep 21, 2023 09:31 am ET
Thinking about buying stock in Neptune Wellness Solutions, Kezar Life Sciences, Avinger, Canopy Growth Corp, or Nio Inc?
NEW YORK, Sept. 21, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEPT, KZR, AVGR, CGC, and NIO.
Sep 19, 2023 09:31 am ET
Thinking about buying stock in Limbach Holdings, Avinger, Rackspace Technology, Keller Group, or Hyzon Motors?
NEW YORK, Sept. 19, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LMB, AVGR, RXT, KLR, and HYZN.
Sep 18, 2023 08:00 am ET
Avinger Initiates Full Commercial Launch of Tigereye ST Image-Guided CTO Crossing Device
REDWOOD CITY, CA / ACCESSWIRE / September 18, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced full commercial launch of its Tigereye® ST next generation image-guided chronic total occlusion (CTO) crossing system. With the initiation of full commercial launch, all current and prospective accounts can now order the Tigereye ST device.
Aug 24, 2023 08:00 am ET
Avinger Announces Presentations by Key Opinion Leaders at AMP (The Amputation Prevention Symposium) 2023
REDWOOD CITY, CA / ACCESSWIRE / August 24, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced three podium presentations featuring the company's Lumivascular technology at The Amputation Prevention Symposium, held from August 16 through August 19 in Chicago, Illinois.
Aug 04, 2023 09:00 am ET
Avinger Announces Conversion of 12% of CRG Term Debt into Equity
REDWOOD CITY, CA / ACCESSWIRE / August 4, 2023 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the conversion of approximately 12% of its existing debt with entities affiliated with CRG Partners III L.P. ("CRG") into shares of a new series of convertible preferred stock.
Jul 20, 2023 08:00 am ET
Avinger to Announce Second Quarter 2023 Results on July 27
REDWOOD CITY, CA / ACCESSWIRE / July 20, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the second quarter 2023 after the close of trading on Thursday, July 27, 2023. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
Jun 20, 2023 08:00 am ET
Avinger Announces Presentations by Key Opinion Leaders at LINC 2023
REDWOOD CITY, CA / ACCESSWIRE / June 20, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced two podium presentations featuring the company's Lumivascular technology at the Leipzig Interventional Course (LINC) 2023, which took place June 6 through June 9. LINC is a leading global forum for new methods and technology in the field of vascular medicine held each year in Leipzig, Germany.
Jun 09, 2023 08:00 am ET
Avinger Announces Presentations by Key Opinion Leaders at New Cardiovascular Horizons Annual Conference
REDWOOD CITY, CA / ACCESSWIRE / June 9, 2023 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced two podium presentations featuring the company's Lumivascular technology at the New Cardiovascular Horizons (NCVH) annual conference, which took place May 30 through June 2 in New Orleans.
Jun 07, 2023 08:00 am ET
Avinger Receives 510(k) Clearance for Pantheris LV Image-Guided Atherectomy System
REDWOOD CITY, CA / ACCESSWIRE / June 7, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced the company has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for Pantheris® LV, its next-generation image-guided atherectomy system for the treatment of peripheral artery disease (PAD).
Jun 05, 2023 08:00 am ET
Avinger Announces Successful First Cases with Tigereye ST Image-Guided Chronic Total Occlusion (CTO) Crossing Device
REDWOOD CITY, CA / ACCESSWIRE / June 5, 2023 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced the successful completion of the first clinical cases with the new Tigereye ST image-guided CTO crossing system.
May 10, 2023 04:01 pm ET
Avinger Reports First Quarter 2023 Results
REDWOOD CITY, CA / ACCESSWIRE / May 10, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the first quarter ended March 31, 2023.
May 02, 2023 08:00 am ET
Avinger to Announce First Quarter 2023 Results on May 10
REDWOOD CITY, CA / ACCESSWIRE / May 2, 2023 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the first quarter 2023 after the close of trading on Wednesday, May 10, 2023. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
Apr 28, 2023 08:00 am ET
Leading Data on the Treatment of In-Stent Restenosis with Pantheris Presented at Charing Cross International Symposium
REDWOOD CITY, CA / ACCESSWIRE / April 28, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the presentation of clinical data from the INSIGHT study during the Charing Cross (CX) International Symposium in London, England. The CX Symposium is a leading vascular and endovascular education conference focused on education, innovation, and evidence. The INSIGHT trial was designed to evaluate the s
Apr 26, 2023 08:00 am ET
Avinger Receives 510(k) Clearance for Tigereye ST Image-Guided CTO Crossing System
REDWOOD CITY, CA / ACCESSWIRE / April 26, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced the company has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for Tigereye® ST, its next-generation image-guided chronic total occlusion (CTO) crossing system.
Mar 15, 2023 04:01 pm ET
Avinger Reports Fourth Quarter 2022 Results
REDWOOD CITY, CA / ACCESSWIRE / March 15, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the fourth quarter and full year ended December 31, 2022.
Mar 02, 2023 08:00 am ET
Avinger to Announce Fourth Quarter 2022 Results on March 15
REDWOOD CITY, CA / ACCESSWIRE / March 2, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the fourth quarter and full year 2022 after the close of trading on Wednesday, March 15, 2023. The Company will host a conference call beginning at 1:30 pm PT/4:30 pm ET.
Jan 11, 2023 08:15 am ET
Avinger Announces 510(k) Filing of Pantheris LV
Pantheris LV Represents the Next-Generation of Onboard Image-Guided Technology for the Treatment of Peripheral Artery Disease
Nov 09, 2022 04:01 pm ET
Avinger Reports Third Quarter 2022 Results
REDWOOD CITY, CA / ACCESSWIRE / November 9, 2022 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the third quarter ended September 30, 2022.
Nov 04, 2022 08:00 am ET
Avinger Announces Issuance of Seven New Patents Expanding Coverage for Its Proprietary Image-Guided Atherectomy Devices
REDWOOD CITY, CA / ACCESSWIRE / November 4, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the issuance of seven new U.S. and international patents in the second and third quarters of 2022 and provided an update on the expansion of its intellectual property portfolio.
Nov 01, 2022 07:45 am ET
Avinger to Announce Third Quarter 2022 Results on November 9
REDWOOD CITY, CA / ACCESSWIRE / November 1, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the third quarter 2022 after the close of trading on Wednesday, November 9, 2022. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
Oct 19, 2022 08:00 am ET
Avinger to Present at LD Micro Investor Conference
REDWOOD CITY, CA / ACCESSWIRE / October 19, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced that Chief Executive Officer Jeff Soinski will participate in the following investor conference event during October 2022.
Sep 07, 2022 08:30 am ET
BrightInsight Adds Medical Device and Biopharmaceutical Experts, Tamara Elias, M.D., and Scott Huennekens to Advisory Council
BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive...
Sep 01, 2022 08:00 am ET
Interim Data from IMAGE-BTK Clinical Trial Presented at AMP 2022
REDWOOD CITY, CA / ACCESSWIRE / September 1, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the presentation of interim data from the IMAGE-BTK clinical study for Pantheris SV at the annual AMP (Amputation Prevention Symposium) conference in August.
Aug 11, 2022 04:05 pm ET
Avinger Reports Second Quarter 2022 Results
REDWOOD CITY, CA / ACCESSWIRE / August 11, 2022 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the second quarter ended June 30, 2022.
Aug 08, 2022 03:15 pm ET
Avinger, Inc. Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-the-Market Under Nasdaq Rules
REDWOOD CITY, CA / ACCESSWIRE / August 8, 2022 / Avinger, Inc. (NASDAQ:AVGR) (the "Company"), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the closing of its previously announced registered direct and private placement offerings priced at-the-market under Nasdaq rules, including the issuance and sale of (i) 700,000 shares of common stock and 784,019 pre-funded warrants in the registered direct offering and (ii) 1
Aug 05, 2022 08:00 am ET
Avinger to Announce Second Quarter 2022 Results on August 11
REDWOOD CITY, CA / ACCESSWIRE / August 5, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the second quarter 2022 after the close of trading on Thursday, August 11, 2022. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
Aug 04, 2022 08:00 am ET
Avinger Announces $5 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules
REDWOOD CITY, CA / ACCESSWIRE / August 4, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced that it has entered into a definitive agreement with a single, healthcare-focused institutional investor for the sale and issuance of 1,484,019 shares of the Company's common stock (or pre-funded warrants in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. Concurr
Jul 06, 2022 08:00 am ET
Avinger Announces Filing of 510(k) Submission for Tigereye ST Image-Guided CTO Crossing System
REDWOOD CITY, CA / ACCESSWIRE / July 6, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the company has submitted a 510(k) application to the U.S. Food & Drug Administration (FDA) for the Tigereye ST catheter, a next generation chronic total occlusion (CTO) crossing system utilizing Avinger's proprietary image-guided technology platform.
Jun 21, 2022 07:30 am ET
Avinger Expands International Presence with First Commercial Shipment to Chile
REDWOOD CITY, CA / ACCESSWIRE / June 21, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the expansion of its international presence with the commercial launch of its Lumivascular products in Chile. Avinger's new Lightbox 3 imaging console will be used exclusively to support the launch of the Lumivascular platform in Chile.
Jun 15, 2022 08:30 am ET
Avinger Announces Presentations by Key Opinion Leaders and Live Case Transmission at LINC 2022
REDWOOD CITY, CA / ACCESSWIRE / June 15, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced two podium presentations and a live case transmission featuring the company's Lumivascular technology at the Leipzig Interventional Course (LINC) 2022, which took place June 6 through June 9. LINC is a leading global forum for new methods and technology in the field of vascular medicine held each year in
Jun 06, 2022 08:30 am ET
Avinger Announces Presentations by Key Opinion Leaders at New Cardiovascular Horizons Annual Conference
REDWOOD CITY, CA / ACCESSWIRE / June 6, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced two podium presentations featuring the company's Lumivascular technology at the New Cardiovascular Horizons (NCVH) annual conference, which took place May 31 through June 3 in New Orleans.
May 20, 2022 09:31 am ET
Thinking about buying stock in Nio, Exicure, Avinger, Covetrus, or Rocket Pharmaceuticals?
NEW YORK, May 20, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, XCUR, AVGR, CVET, and RCKT.
May 16, 2022 08:00 am ET
Avinger Announces Key Opinion Leader Presentation and Live Case at Vascular Conferences in Germany
REDWOOD CITY, CA / ACCESSWIRE / May 16, 2022 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced a key opinion leader (KOL) presentation and a live-case event featuring the Company's Lumivascular technology at two important vascular conferences in Germany: the annual CLI Congress on May 6-7 and Masterclass Münster on May 9-10.
May 10, 2022 04:02 pm ET
Avinger Reports First Quarter 2022 Results
REDWOOD CITY, CA / ACCESSWIRE / May 10, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the first quarter ended March 31, 2022.
Apr 29, 2022 09:00 am ET
Avinger to Announce First Quarter 2022 Results on May 10
REDWOOD CITY, CA / ACCESSWIRE / April 29, 2022 / Avinger, Inc. (Nasdaq:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the first quarter 2022 after the close of trading on Tuesday, May 10, 2022. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
Apr 19, 2022 08:00 am ET
Avinger Announces Full Commercial Launch of Lightbox 3
REDWOOD CITY, CA / ACCESSWIRE / April 19, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced full commercial availability of its new Lightbox 3 imaging console designed to enhance the user experience and drive faster adoption at new hospital sites.
Mar 30, 2022 08:00 am ET
Avinger Announces Issuance of Three New U.S. Patents in March 2022
16 New U.S. and International Patents Issued over Past Year
Mar 29, 2022 04:05 pm ET
Avinger Regains Compliance with Nasdaq Listing Requirements
REDWOOD CITY, CA / ACCESSWIRE / March 29, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced it has regained compliance with Nasdaq listing requirements.
Mar 22, 2022 04:01 pm ET
Avinger Reports Fourth Quarter and Year End 2021 Results
REDWOOD CITY, CA / ACCESSWIRE / March 22, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the fourth quarter and full year ended December 31, 2021.
Mar 22, 2022 09:31 am ET
Thinking about buying stock in Draganfly, Enservco, Avinger, Hall of Fame Resort & Entertainment, or Tcr2 Therapeutics?
NEW YORK, March 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DPRO, ENSV, AVGR, HOFV, and TCRR.
Mar 15, 2022 08:35 am ET
Thinking about buying stock in Hycroft Mining, Excellon Resources, Avinger, Pearson, or Arcadia Biosciences?
NEW YORK, March 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HYMC, EXN, AVGR, PSO, and RKDA.
Mar 15, 2022 07:30 am ET
Avinger to Announce Full-Year 2021 Results on March 22
REDWOOD CITY, CA / ACCESSWIRE / March 15, 2022 / Avinger, Inc. (NASDAQ:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the fourth quarter and full year 2021 after the close of trading on Tuesday, March 22, 2021. The Company will host a conference call beginning at 1:30 pm PT/4:30 pm ET.
Mar 14, 2022 08:00 am ET
Avinger to Effect One-for-Twenty Reverse Stock Split
REDWOOD CITY, CA / ACCESSWIRE / March 14, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that the Company will effect a 1-for-20 reverse stock split of the Company's common stock, which will be effective at 5:00 p.m. Eastern time on Monday, March 14, 2022. As of that date, each twenty shares of issued and outstanding common stock and equivalents will be converted into one s
Mar 07, 2022 07:30 am ET
Avinger Expands Lightbox 3 First Case Experience
Patients Treated in Four Additional Hospitals Using New Portable System
Feb 28, 2022 08:15 am ET
Avinger Announces Successful Completion of First Cases with the Lightbox 3 Next Generation Imaging Console
REDWOOD CITY, CA / ACCESSWIRE / February 28, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that physicians in the U.S. have successfully completed first cases with its new Lightbox 3 imaging console. The Lightbox 3 received 510(k) pre-marketing clearance from the U.S. Food & Drug Administration (FDA) in January. Avinger is expanding availability of the Lightbox 3 to additional sites on
Jan 14, 2022 04:01 pm ET
Avinger Announces Closing of $7.6 Million Registered Direct Offering
REDWOOD CITY, CA / ACCESSWIRE / January 14, 2022 / Avinger, Inc. (NASDAQ:AVGR) (the "Company"), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the closing of its previously announced registered direct offering of an aggregate of 7,600 shares of Series D convertible preferred stock (the "Preferred Stock") and warrants to purchase up to an aggregate of 16,150,000 shares of common stock to certain institution
Jan 12, 2022 09:50 am ET
Thinking about buying stock in Zynga, Petroleo Brasileiro, Opendoor Technologies, Avinger, or Marathon Digital?
NEW YORK, Jan. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZNGA, PBR, OPEN, AVGR, and MARA.
Jan 12, 2022 08:00 am ET
Avinger Announces $7.6 Million Registered Direct Offering
REDWOOD CITY, CA / ACCESSWIRE / January 12, 2022 / Avinger, Inc. (NASDAQ:AVGR) (the "Company"), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale in a registered direct offering of an aggregate of 7,600 shares of Series D convertible preferred stock (the "Preferred Stock") and warrants to purchase up
Jan 11, 2022 08:30 am ET
Avinger Announces 510(k) Clearance for Lightbox 3 Next-Generation Imaging Console
REDWOOD CITY, CA / ACCESSWIRE / January 11, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its new Lightbox 3 imaging console.
Jan 10, 2022 08:31 am ET
Thinking about buying stock in Tilray, Avinger, Reliance Global, BioCryst Pharmaceuticals, or Codex DNA?
NEW YORK, Jan. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TLRY, AVGR, RELI, BCRX, and DNAY.
Nov 17, 2021 09:50 am ET
Thinking about buying stock in Avinger, Naked Brand, Bit Brother, Norwegian Cruise Line, or Fisker?
NEW YORK, Nov. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVGR, NAKD, BTB, NCLH, and FSR.
Nov 17, 2021 08:30 am ET
Avinger Announces FDA Clearance of Pantheris for the Treatment of In-Stent Restenosis
New indication expands addressable market for Pantheris
Nov 11, 2021 04:01 pm ET
Avinger Reports Third Quarter 2021 Financial Results
REDWOOD CITY, CA / ACCESSWIRE / November 11, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today reported results for the third quarter ended September 30, 2021.
Oct 29, 2021 08:30 am ET
Avinger to Announce Third Quarter Results on November 11, 2021
REDWOOD CITY, CA / ACCESSWIRE / October 29, 2021 / Avinger, Inc. (NASDAQ:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the third quarter 2021 after the close of trading on Thursday, November 11, 2021. The Company will host a conference call beginning at 1:30 pm PT/4:30 pm ET.
Oct 07, 2021 08:45 am ET
Ground-Breaking Clinical Data from INSIGHT Trial Presented at VIVA
Study Outcomes Demonstrate Safety and Efficacy of Pantheris for Treatment of In-Stent Restenosis
Sep 08, 2021 08:45 am ET
Avinger To Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15
REDWOOD CITY, CA / ACCESSWIRE / September 8, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that its management will participate in investor meetings September 13-15, 2021 as part of the H.C. Wainwright 23rd Annual Global Investment Conference.
Aug 16, 2021 08:00 am ET
Avinger OCT-Guided Technologies Featured at AMP 2021
REDWOOD CITY, CA / ACCESSWIRE / August 16, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced presentations featuring the Company's Lumivascular, OCT-guided, technologies at the annual AMP (Amputation Prevention Symposium) conference occurring last week.
Aug 10, 2021 04:01 pm ET
Avinger Reports Second Quarter 2021 Financial Results
Pantheris Sales and Tigereye™ Expansion Drive 91% Year-Over-Year Revenue Growth
Aug 09, 2021 07:30 am ET
Avinger Announces 510(k) Filing for New Lightbox 3 Imaging Console
Smaller Footprint, Improved User Experience and Lower Cost to Drive Adoption
Jul 27, 2021 04:00 pm ET
Avinger to Announce Second Quarter 2021 Results on August 10, 2021
REDWOOD CITY, CA / ACCESSWIRE / July 27, 2021 / Avinger, Inc. (Nasdaq:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the second quarter 2021 after the close of trading on Tuesday, August 10, 2021. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
Jul 13, 2021 09:31 am ET
Thinking about buying stock in Nokia, Clovis Oncology, Avinger, Ericsson, or New Oriental Education?
NEW YORK, July 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOK, CLVS, AVGR, ERIC, and EDU.
Jul 06, 2021 08:30 am ET
Avinger Announces 510(k) Filing for New Pantheris In-Stent Restenosis Indication
REDWOOD CITY, CA / ACCESSWIRE / July 6, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the submission of a 510(k) application to the U.S. Food & Drug Administration (FDA) for a new Pantheris clinical indication for the treatment of in-stent restenosis (ISR) in the lower extremity arteries.
Jun 29, 2021 08:30 am ET
Thinking about buying stock in Exela Technologies, Cerevel Therapeutics, Verb Technology, Avinger, or VBI Vaccines?
NEW YORK, June 29, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XELA, CERE, VERB, AVGR, and VBIV.
Jun 28, 2021 08:45 am ET
Avinger Announces Key Opinion Leader Presentations at Vascular Conferences in Germany
REDWOOD CITY, CA / ACCESSWIRE / June 28, 2021 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced key opinion leader (KOL) presentations featuring the company's Lumivascular technology at two important vascular conferences held in Germany: the annual German CLI Congress and the Essen Vascular Conference.
Jun 07, 2021 08:00 am ET
Avinger Announces Presentations by Key Opinion Leaders at New Cardiovascular Horizons Annual Conference
REDWOOD CITY, CA / ACCESSWIRE / June 7, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced two podium presentations featuring the company's Lumivascular technology at the New Cardiovascular Horizons (NCVH) annual conference, which took place June 1 through June 4 in New Orleans.
May 25, 2021 08:30 am ET
Avinger Announces Issuance and Allowance of Seven U.S. Patents
REDWOOD CITY, CA / ACCESSWIRE / May 25, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the issuance and allowance of seven U.S. patents to date in 2021.
May 17, 2021 08:00 am ET
Avinger To Present at the Oppenheimer MedTech, Tools & Diagnostics Summit May 26
REDWOOD CITY, CA / ACCESSWIRE / May 17, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that its management will host investor meetings on May 26, 2021 as part of the Oppenheimer MedTech, Tools & Diagnostics Summit.
May 06, 2021 04:01 pm ET
Avinger Reports First Quarter 2021 Financial Results
13% Year-over-Year Revenue Growth Driven by Tigereye™ Commercial Launch and Pantheris SV Sales Growth
Apr 26, 2021 08:30 am ET
Avinger to Announce First Quarter 2021 Results on May 6, 2021
REDWOOD CITY, CA / ACCESSWIRE / April 26, 2021 / Avinger, Inc. (NASDAQ:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the first quarter 2021 after the close of trading on Thursday, May 6, 2021. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
Apr 21, 2021 08:00 am ET
New Publications Highlight Clinical Benefits of Avinger PAD Therapies
REDWOOD CITY, CA / ACCESSWIRE / April 21, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the publication of two clinical studies in peer-reviewed journals, further supporting the clinical benefits of its therapeutic devices. The studies were based on separate clinical case series conducted by physicians at the Division of Cardiovascular Disease and Endovascular Medicine at the Einstein Medical Center
Apr 15, 2021 08:00 am ET
Avinger Achieves Commercial Milestone with More Than 100 Accounts Using Pantheris SV
REDWOOD CITY, CA / ACCESSWIRE / April 15, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today reported that more than 100 accounts have purchased Pantheris SV OCT-guided atherectomy catheters for the treatment of PAD since product launch in the third quarter of 2019.
Apr 08, 2021 08:30 am ET
Avinger Provides Update on Tigereye(TM) Commercial Launch
REDWOOD CITY, CA / ACCESSWIRE / April 8, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today provided an update on the commercial launch of Tigereye CTO Crossing catheters for the treatment of PAD.
Mar 11, 2021 04:01 pm ET
Avinger Reports Fourth Quarter 2020 Financial Results
19% Sequential Increase in Total Revenue
Mar 11, 2021 08:35 am ET
Avinger, Inc. to Present at the Q1 Virtual Investor Summit
via InvestorWire- Avinger, Inc. (Nasdaq: AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced...
Mar 02, 2021 08:00 am ET
Avinger to Announce Fourth Quarter Full Year 2020 Results on March 11, 2021
REDWOOD CITY, CA / ACCESSWIRE / March 2, 2021 / Avinger, Inc. (NASDAQ:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the fourth quarter and full year 2020 after the close of trading on Thursday, March 11, 2021. The Company will host a conference call beginning at 1:30 pm PT/4:30 pm ET.
Feb 18, 2021 07:30 am ET
Thinking about buying stock in Avinger, Rigel Pharmaceuticals, Vistagen Therapeutics, Bio-Path, or Corvus Pharmaceuticals?
NEW YORK, Feb. 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVGR, RIGL, VTGN, BPTH, and CRVS.
Feb 03, 2021 01:50 pm ET
Aegis Capital Corp. acted as Sole Bookrunner on a $14.4 Million Bought Deal Offering for Avinger, Inc. (NASDAQ: AVGR)
NEW YORK, NY / ACCESSWIRE / February 3, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $14.4 Million Bought Deal Offering for Avinger, Inc. (NASDAQ:AVGR)
Feb 03, 2021 08:00 am ET
Avinger Tigereye CTO Crossing Featured in Live Case at LINC 2021
REDWOOD CITY, CA / ACCESSWIRE / February 3, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that its Tigereye™ CTO crossing system and Pantheris atherectomy system were featured in a live case transmission on January 29 at the Leipzig Interventional Course (LINC) 2021. LINC is a leading global forum for new methods and technology in the field of vascular medicine held each year in Leipzig, Germa
Feb 02, 2021 11:25 am ET
Avinger Closes $14.4 Million Bought Deal Offering of Common Stock
REDWOOD CITY, CA / ACCESSWIRE / February 2, 2021 / Avinger, Inc. (NASDAQ:AVGR) (the "Company"), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the closing of an underwritten offering of 10,000,000 shares of common stock of the Company, at a price to the public of $1.44 per share.
Jan 28, 2021 04:45 pm ET
Avinger Announces $14.4 Million Bought Deal Offering of Common Stock
REDWOOD CITY, CA / ACCESSWIRE / January 28, 2021 / Avinger, Inc. (NASDAQ:AVGR) (the "Company"), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it has entered into an underwriting agreement with Aegis Capital Corp. under which the underwriter has agreed to purchase, on a firm commitment basis, 10,000,000 shares of common stock of the Company, at a price to the public of $1.44 per share (the "Public Price"), repr
Jan 27, 2021 08:30 am ET
Avinger Regains Compliance with Nasdaq Listing Requirements
REDWOOD CITY, CA / ACCESSWIRE / January 27, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced it has regained compliance with Nasdaq listing requirements.
Jan 26, 2021 08:30 am ET
Avinger Improves Terms of Existing CRG Loan Agreement
REDWOOD CITY, CA / ACCESSWIRE / January 26, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced an agreement with CRG Partners III L.P. to extend the interest only period and maturity date of its existing term loan.
Jan 19, 2021 08:30 am ET
Avinger Expands Intellectual Property Portfolio
19 New U.S. and International Patents Issued and Allowed in 2020
Jan 15, 2021 08:30 am ET
Avinger Initiates Full Commercial Launch of Tigereye(TM) Image-Guided CTO Crossing Catheter
REDWOOD CITY, CA / ACCESSWIRE / January 15, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced full commercial launch of its Tigereye™ image-guided chronic total occlusion (CTO) crossing system. With the initiation of full commercial launch, current and prospective accounts throughout the US and Germany are now able to order the Tigereye device.
Jan 06, 2021 04:05 pm ET
Avinger to Participate in HC Wainwright Conference
REDWOOD CITY, CA / ACCESSWIRE / January 6, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that its executive team will participate in the H.C. Wainwright Bioconnect 2021 Conference taking place virtually January 11-14, 2021. Management will provide a pre-recorded presentation, which will be available to registered investors on demand via the conference website beginning January 11. Avinger will also provide a link
Dec 23, 2020 04:50 pm ET
Avinger Announces Annual Meeting Results
REDWOOD CITY, CA / ACCESSWIRE / December 23, 2020 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced results of its annual meeting of stockholders (the "Annual Meeting"), concluded on December 23, 2020.
Dec 11, 2020 07:30 am ET
Avinger Adjourns Annual Meeting of Stockholders
Scheduled to Reconvene December 23, 2020
Dec 04, 2020 08:30 am ET
Avinger Expands Tigereye(TM) Limited Launch
REDWOOD CITY, CA / ACCESSWIRE / December 4, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today provided an update on the limited launch of its Tigereye™ next generation image-guided chronic total occlusion (CTO) crossing system. Avinger is conducting a limited launch at clinical centers in the U.S. and Germany during the fourth quarter of 2020 prior to a planned expansion to full U.S. commercial distr
Dec 01, 2020 08:30 am ET
Avinger Receives Nasdaq Extension, Recommends Stockholders Vote FOR All Proxy Proposals
REDWOOD CITY, CA / ACCESSWIRE / December 1, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the company has received an extension until May 19, 2021 to regain compliance with the Nasdaq minimum bid price requirement for continued listing. The company previously had until November 20, 2020 to regain compliance, and received its extension notice on November 24, 2020.
Nov 10, 2020 04:01 pm ET
Avinger Reports Third Quarter 2020 Financial Results
57% Sequential Increase in Revenue
Nov 05, 2020 08:00 am ET
Avinger Announces Commercial Launch in Israel
REDWOOD, CA / ACCESSWIRE / November 5, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the commercial launch of its Lumivascular products and completion of its first patient cases in Israel.
Oct 28, 2020 08:30 am ET
Avinger to Announce Third Quarter 2020 Results on November 10, 2020
REDWOOD CITY, CA / ACCESSWIRE / October 28, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that it will release its financial results for the third quarter 2020 after the close of trading on Tuesday, November 10, 2020. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
Oct 19, 2020 07:00 am ET
Avinger Announces First US Cases with TIGEREYE(TM) Image-Guided CTO Crossing Catheter
REDWOOD CITY, CA / ACCESSWIRE / October 19, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that physicians in three U.S. sites have successfully treated patients with the TIGEREYE™ next generation image-guided chronic total occlusion (CTO) crossing system. These cases are part of a limited launch at up to 10 top clinical centers prior to expanding commercial distribution to additional treatment
Sep 11, 2020 08:30 am ET
Avinger Receives FDA Clearance of Ocelaris Next Generation Image-guided CTO Crossing System
Innovative New Product to be Marketed under TIGEREYE™ Brand Name
Sep 01, 2020 01:05 pm ET
Avinger Announces Exercise and Closing of Underwriter's Over-Allotment
REDWOOD CITY, CA / ACCESSWIRE / September 1, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease ("PAD"), today announced that the underwriter of its previously announced underwritten public offering has exercised, in full, their option to purchase an additional 1,000,000 shares of the Company's common stock at a price of $0.47 per share. Total gross proceeds to the Company from the offering, includi
Aug 31, 2020 10:50 am ET
Aegis Capital Corp. acted as Sole Bookrunner on a $5.2 Million Follow-On Offering for Avinger Inc. (NASDAQ: AVGR)
NEW YORK, NY / ACCESSWIRE / August 31, 2020 / Aegis Capital Corp. acted as Sole Bookrunner on a $5.2 Million Follow-On Offering for Avinger Inc. (NASDAQ:AVGR)
Aug 25, 2020 12:00 pm ET
Avinger Closes $5.2 Million Underwritten Public Offering of Common Stock
REDWOOD CITY, CA / ACCESSWIRE / August 25, 2020 / Avinger, Inc. (NASAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the closing of an underwritten public offering of 11,063,830 shares of its common stock at a price of $0.47 per share, for total gross proceeds of approximately $5.2 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally,
Aug 20, 2020 08:45 pm ET
Avinger Prices $5.2 Million Underwritten Public Offering of Common Stock
REDWOOD CITY, CA / ACCESSWIRE / August 20, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $5.2 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.
Aug 11, 2020 10:05 am ET
Avinger Announces Exercise and Closing of Underwriter’s Over-Allotment
REDWOOD CITY, CA / ACCESSWIRE / August 11, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease ("PAD"), today announced that the underwriters of its previously announced underwritten public offering have exercised, in full, their option to purchase an additional 2,368,421 shares of the Company's common stock at a price of $0.38 per share. Total gross proceeds to the Company from the Offering, includi
Aug 10, 2020 12:20 pm ET
Aegis Capital Corp. acted as Sole Bookrunner on a $6,000,000 Follow-On Offering for Avinger Inc. (NASDAQ:AVGR)
NEW YORK, NY / ACCESSWIRE / August 10, 2020 / Aegis Capital Corp. acted as Sole Bookrunner on a $6,000,000 Follow-On Offering for Avinger Inc. (NASDAQ:AVGR)
Aug 06, 2020 12:30 pm ET
Avinger Closes $6 Million Underwritten Public Offering of Common Stock
REDWOOD CITY, CA / ACCESSWIRE / August 6, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the closing of an underwritten public offering of 15,789,474 shares of its common stock at a price of $0.38 per share, for total gross proceeds of approximately $6 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, t
Aug 03, 2020 08:05 pm ET
Avinger Prices $6 Million Underwritten Public Offering of Common Stock
REDWOOD CITY, CA / ACCESSWIRE / August 3, 2020 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $6 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.
Jul 30, 2020 04:01 pm ET
Avinger Reports Second Quarter 2020 Financial Results
REDWOOD CITY, CA / ACCESSWIRE / July 30, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported results for the second quarter ended June 30, 2020.
Jul 27, 2020 08:30 am ET
Avinger to Announce Second Quarter 2020 Results on July 30, 2020
REDWOOD, CA / ACCESSWIRE / July 27, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that it will release its financial results for the second quarter 2020 after the close of trading on Thursday, July 30, 2020. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
Jul 09, 2020 11:50 am ET
Avinger Announces Exercise and Closing of Underwriter's Over-Allotment Offering
REDWOOD CITY, CA / ACCESSWIRE / July 9, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease ("PAD"), today announced that the underwriters of its previously announced underwritten public offering have exercised, in full, their option to purchase an additional 3,000,000 shares of its common stock at a price of $0.27 per share. Total gross proceeds to the Company from the Offering, including the funds rece
Jun 29, 2020 12:15 pm ET
Aegis Capital Corp. acted as Sole Bookrunner on a $5,400,000 Follow-On Offering for Avinger Inc. (NASDAQ: AVGR)
NEW YORK, NY / ACCESSWIRE / June 29, 2020 / Aegis Capital Corp. acted as Sole Bookrunner on a $5,400,000 Follow-On Offering for Avinger Inc. (NASDAQ:AVGR)
Jun 26, 2020 02:20 pm ET
Avinger Closes $5.4 Million Underwritten Public Offering of Common Stock
REDWOOD CITY, CA / ACCESSWIRE / June 26, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the closing of an underwritten public offering of 20,000,000 shares of its common stock at a price of $0.27 per share, for total gross proceeds of approximately $5.4 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the Com
Jun 23, 2020 08:40 pm ET
Avinger Prices $5.4 Million Underwritten Public Offering of Common Stock
REDWOOD CITY, CA / ACCESSWIRE / June 23, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be $5.4 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.
May 20, 2020 08:30 am ET
Avinger Announces 510(k) Filing of Ocelaris Next Generation Image-guided CTO Crossing System
REDWOOD CITY, CA / ACCESSWIRE / May 20, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the Company has submitted a 510(k) application to the U.S. Food & Drug Administration (FDA) for pre-marketing clearance of Ocelaris, a next generation chronic total occlusion (CTO) crossing system utilizing Avinger's proprietary image-guided technology platform.
May 13, 2020 04:01 pm ET
Avinger Reports First Quarter 2020 Financial Results
23% Year-Over-Year Revenue Growth
May 07, 2020 09:00 am ET
Avinger to Announce First Quarter 2020 Results on May 13, 2020
REDWOOD CITY, CA / ACCESSWIRE / May 7, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that it will release its financial results for the first quarter 2020 after the close of trading on Wednesday, May 13, 2020. The Company will host a conference call beginning at 1:30 pm PT/4:30 pm ET.
May 06, 2020 12:00 pm ET
Avinger Announces Exercise and Closing of Underwriter's Over-Allotment Offering
REDWOOD CITY, CA / ACCESSWIRE / May 6, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 1,890,000 shares of its common stock at a price of $0.25 per share. Total gross proceeds to the Company from the Offering, including the funds received from the p
Apr 30, 2020 11:17 am ET
Avinger Closes $3.15 Million Equity Offering
REDWOOD CITY, CA / ACCESSWIRE / April 30, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the closing of an underwritten public offering of 12,600,000 shares of its common stock at a price of $0.25 per share, for total gross proceeds of approximately $3.15 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the C
Apr 27, 2020 09:25 pm ET
Avinger Prices $3.15 Million Underwritten Public Offering of Common Stock
REDWOOD CITY, CA / ACCESSWIRE / April 27, 2020 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $3.15 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The proposed offering equates to 12.6 million shares of t
Apr 15, 2020 09:00 am ET
Avinger Reports Preliminary First Quarter 2020 Revenue Results
Provides Update on COVID-19 Impact and Response
Mar 05, 2020 04:05 pm ET
Avinger Reports Fourth Quarter 2019 Financial Results
REDWOOD CITY, CA / ACCESSWIRE / March 5, 2020 / Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported results for the fourth quarter and full year ended December 31, 2019.
Feb 27, 2020 08:00 am ET
Avinger to Announce Fourth Quarter 2019 Financial Results on March 5, 2020
REDWOOD CITY, CA / ACCESSWIRE / February 27, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that it will release its financial results for the fourth quarter 2019 after the close of trading on Thursday, March 5, 2020. The Company will host a conference call beginning at 1:30 pm PT/4:30 pm ET.
Feb 25, 2020 08:30 am ET
Avinger Announces Publication of SCAN Clinical Study in Peer-Reviewed Journal
OCT Imaging with Pantheris Superior or Equivalent to IVUS on all Parameters
Feb 04, 2020 08:00 am ET
Avinger's Pantheris Featured in Live Case Transmission at LINC 2020
REDWOOD, CA / ACCESSWIRE / February 4, 2020 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), announced today that its Pantheris atherectomy system was featured in a live case transmission at the Leipzig Interventional Course (LINC) 2020, a leading global forum for new methods in the field of vascular medicine held from January 28 through January 31 in Leipzig, Germany. In addition to performing the live case, Dr. Arne Sch
Jan 31, 2020 04:01 pm ET
Avinger Closes $4.5 Million Equity Offering
REDWOOD CITY, CA / ACCESSWIRE / January 31, 2020 / Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD) today announced the closing of an underwritten public offering of 6,428,572 shares of its common stock at a price of $0.70 per share, for total gross proceeds of approximately $4.5 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the Company has granted the underwriters a 45-day option to purchase up to 15% additional shares of common stock to cover o
Jan 30, 2020 08:30 am ET
Avinger Announces the Passing of Director Donald A. Lucas
REDWOOD CITY, CA / ACCESSWIRE / January 30, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the death of Donald A. Lucas, independent director and chairman of the audit committee, on Tuesday, January 28, 2020.
Jan 28, 2020 08:05 pm ET
Avinger Prices $4.5 Million Underwritten Public Offering of Common Stock
REDWOOD CITY, CA / ACCESSWIRE / January 28, 2020 / Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $4.5 million before deducting underwriting discounts and commissions and other estimated offering expenses. The proposed offering equates to 6,428,572 shares of the Company's common stock at a price of $0.70 per share. The Company intends to use the net proceeds from this offering to fund wor
Jan 23, 2020 08:00 am ET
Avinger Enrolls First Patient in IMAGE-BTK Clinical Study Evaluating Safety and Efficacy Endpoints for Pantheris SV
Post-Market Study Intended to Support Commercial Expansion of Small Vessel Image-Guided Atherectomy Device
Jan 09, 2020 08:30 am ET
Avinger Announces Successful First Procedures in Europe with Ocelaris Chronic Total Occlusion (CTO) Image-Guided Crossing Device
REDWOOD CITY, CA / ACCESSWIRE / January 9, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the first clinical experiences with the Ocelaris next-generation CTO crossing system utilizing Avinger's proprietary image-guided technology platform.
Dec 17, 2019 08:30 am ET
Avinger Receives CE Marking for Ocelaris, a Next-Generation Image-Guided CTO Crossing System
REDWOOD CITY, CA / ACCESSWIRE / December 17, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based systems for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced it has gained Conformité Européenne (CE) Marking for Ocelaris, a next-generation chronic total occlusion (CTO) crossing system utilizing Avinger's proprietary image-guided technology platform. CE Marking allows clinical use of Ocelaris in the European Union (EU) and certain other countries t
Dec 16, 2019 08:30 am ET
Avinger Appoints Healthcare Veteran Tamara Elias, MD, to Board of Directors
REDWOOD, CA / ACCESSWIRE / December 16, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), is pleased to announce that Tamara Elias, MD, has been appointed to the Company's Board of Directors, effective December 12, 2019. Dr. Elias has been actively involved with healthcare for more than 20 years in strategic consulting, private equity
Nov 05, 2019 04:01 pm ET
Avinger Reports Third Quarter 2019 Financial Results
Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported...
Oct 29, 2019 09:00 am ET
Avinger to Announce Third Quarter 2019 Financial Results on November 5, 2019
REDWOOD CITY, CA / ACCESSWIRE / October 29, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that it will release its financial results for the third quarter 2019 after the close of trading on Tuesday, November 5, 2019. The Company will host a conference call beginning at 4:30pm ET.
Oct 09, 2019 08:00 am ET
Avinger Expands US Reach with Seven New Accounts in Third Quarter
Includes New Sites in Florida, Georgia and Arizona PAD Markets
Sep 18, 2019 08:00 am ET
Avinger Announces Full Commercial Launch of Pantheris SV
Product Shipped to 25 U.S. Accounts
Sep 17, 2019 08:00 am ET
Avinger to Present at Ladenburg Thalmann Healthcare Conference on September 24
REDWOOD CITY, CA / ACCESSWIRE / September 17, 2019 / Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced today announced that Jeff Soinski, CEO, will present at the Ladenburg Thalmann Healthcare Conference on Tuesday, September 24, 2019, at 2:00 pm Eastern Time, at the Sofitel Hotel in New York City. The presentation will be webcast, both live and in an archived format, with a link available at www.avinger.com under “Investors,” then “Events &a
Sep 10, 2019 08:00 am ET
Avinger Announces Commercial Launch and First Patients Treated in Hong Kong
REDWOOD CITY, CA / ACCESSWIRE / September 10, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the commercial launch of its Lumivascular products in Hong Kong. Avinger has an exclusive distribution agreement with Integmed Ltd. for the sale and marketing of Avinger’s Pantheris image-guided atherectomy and Ocelot image-guided chronic total occlusion (CTO
Sep 04, 2019 08:30 am ET
Avinger Supports Peripheral Artery Disease (PAD) Awareness Month with Physician and Patient Programs in September
REDWOOD CITY, CA / ACCESSWIRE / September 4, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), urges greater awareness for this disease state in support of PAD Awareness Month in September. Avinger plans to support PAD Awareness Month through the distribution of informational articles and content related to PAD throughout September, directed both at physicians and patients.
Aug 29, 2019 08:00 am ET
Avinger Announces 50th Patient Treated in Pantheris SV Initial Launch
Preparing for Full Commercial Launch in September
Aug 26, 2019 04:02 pm ET
Avinger Closes $4.5 Million Equity Offering
Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD) today announced the closing of an underwritten public offering of 3,813,559 shares of its common stock at a price of $1.18 per share, for...
Aug 21, 2019 09:00 pm ET
Avinger Prices $4.5 Million Underwritten Public Offering of Common Stock
Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $4.5...
Aug 21, 2019 04:15 pm ET
Avinger Announces Proposed Underwritten Public Offering of Common Stock
Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, the...
Aug 19, 2019 07:00 am ET
Avinger Announces Presentations by Key Opinion Leaders at AMP 2019 Clinical Conference
REDWOOD, CA / ACCESSWIRE / August 19, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced four podium presentations featuring the Company’s Lumivasc
Jul 31, 2019 04:01 pm ET
Avinger Reports 26% Sequential Revenue Growth in Second Quarter 2019
Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported...
Jul 29, 2019 08:00 am ET
Avinger Announces Pantheris SV Limited Launch and Successful Treatment of First Patients in the United States
Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that physicians...
Jul 26, 2019 09:00 am ET
Avinger to Announce Second Quarter 2019 Financial Results on July 31, 2019
Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced...
Jul 16, 2019 08:00 am ET
Avinger Announces Presentations by Key Opinion Leaders at CVC 2019
REDWOOD CITY, CA / ACCESSWIRE / July 16, 2019 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced five podium presentations and a live case featuring the Company’s Lumivascular technology at the a
Jul 10, 2019 09:40 am ET
Avinger Enrolls First 50 Patients in INSIGHT Clinical Trial
Positive early outcomes in complex in-stent restenosis cases with few therapeutic options
Jul 08, 2019 07:30 am ET
Avinger Announces Commercial Launch of Ocelot in Australia
First Patients Treated Successfully in Australia with Image-Guided CTO-Crossing Device
Jun 21, 2019 04:05 pm ET
Avinger to Effect One-for-Ten Reverse Stock Split
Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that the Company will effect a...
Jun 04, 2019 07:00 am ET
Avinger Announces Distribution Agreement for Hong Kong
REDWOOD CITY, CA / ACCESSWIRE / June 4, 2019 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced it has entered into an exclusive distribution agreement with Integmed Ltd. for the sales and marketing of Avinger's Lumivascular products in Hong Kong. Initial product shipments are anticipated during the current quarter and first patient treatments in Hong Kong are expected to commence in the third quarter of 2019.
May 30, 2019 04:00 pm ET
Avinger Announces Presentations by Key Opinion Leaders at New Cardiovascular Horizons Annual Conference
REDWOOD CITY, CA / ACCESSWIRE / May 30, 2019 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced four podium presentations featuring the company's Lumivascular technology at the New Cardiovascular Horizons (NCVH) annual conference, which is taking place this week in New Orleans.
May 08, 2019 04:01 pm ET
Avinger Provides First Quarter 2019 Shareholder Update
Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported...
May 02, 2019 12:25 pm ET
Avinger to Announce First Quarter 2019 Financial Results on May 8, 2019
REDWOOD CITY, CA / ACCESSWIRE / May 2, 2019 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that it will release its financial results for the first quarter 2019 after the close of trading on Wednesday, May 8, 2019. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
Apr 18, 2019 07:55 am ET
Market Trends Toward New Normal in GrafTech International, Avinger, OraSure Technologies, Adamis Pharmaceuticals, Crinetics Pharmaceuticals, and Wayside Technology Group — Emerging Consolidated Expect
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of GrafTech International Ltd. (NYSE:EAF), Avinger, Inc. (NASDAQ:AVGR),...
Apr 17, 2019 08:00 am ET
Avinger Announces Issuance of New U.S. Patent and Receives Notice of Allowance for Five Additional U.S. Patents
Extensive Intellectual Property Portfolio Now Includes 149 Patents and Applications
Apr 15, 2019 08:00 am ET
Avinger Announces Publication of Study Demonstrating Positive Clinical Outcomes for Patients Treated with Pantheris Prior to Antirestenotic Therapy
93% Primary Patency Rate and 100% Freedom from Target Lesion Revascularization at 12 Months
Apr 10, 2019 08:00 am ET
Avinger Receives FDA Clearance of Pantheris SV Device
Avinger, Inc. (Nasdaq: AVGR), a leading developer of image-guided, catheter-based systems for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that the Company received 510(k) clearance from the U.S....
Mar 27, 2019 08:00 am ET
Avinger Receives $6.2 Million from Warrant Exercises
REDWOOD CITY, CA / ACCESSWIRE / March 27, 2019 / Avinger, Inc. (NASDAQ: AVGR), a leading developer of image-guided, catheter-based systems for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD), announced today that it has received $6.2 million in net proceeds from holders exercising common stock purchase warrants at an exercise price of $0.40 per share. The warrants were issued as part of the units sold in the Company's public offering which closed on November 1, 2018. The proceeds from the warrant offering wou
Mar 06, 2019 04:05 pm ET
Avinger Provides Fourth Quarter and Full Year 2018 Shareholder Update
Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported...
Mar 01, 2019 08:30 am ET
Avinger to Present at Oppenheimer Healthcare Conference on March 20
REDWOOD CITY, CA / ACCESSWIRE / March 1, 2019 / Avinger, Inc. (NASDAQ: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced today announced that Jeff Soinski, CEO, will present at the Oppenheimer & Co. 29th Annual Healthcare Conference on Wednesday, March 20, 2019, at 1:00 pm Eastern Time, at the Westin New York Grand Central in New York City.
Feb 28, 2019 08:30 am ET
Avinger to Announce Fourth Quarter and Full Year 2018 Financial Results on March 6, 2019
Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced...
Jan 28, 2019 08:00 am ET
Avinger’s Pantheris SV (Small Vessel) Featured in Live Case Transmission at Leipzig Interventional Course (LINC) 2019
Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that its Pantheris® SV (Small Vessel) image-guided atherectomy system was featured in a live case transmission at...
Dec 19, 2018 06:00 am ET
Avinger Announces Preliminary Analysis of Results from SCAN Clinical Study
Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the release of the preliminary analysis of results from its SCAN clinical study, a post-market study comparing optical...
Dec 13, 2018 07:00 am ET
Avinger Announces Successful Treatment of 500th Patient with Next-Generation Pantheris Device
Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that physicians in 59 sites globally have successfully treated more than 500 patients with the next-generation Pantheris...
Dec 06, 2018 08:00 am ET
Avinger Announces Commercial Launch in Australia
Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today announced the...
Nov 21, 2018 08:50 am ET
Market Trends Toward New Normal in Wilhelmina International, Eyenovia, aTyr Pharma, Avinger, Viacom, and Axsome Therapeutics — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Wilhelmina International, Inc. (NASDAQ:WHLM), Eyenovia, Inc....
Nov 15, 2018 09:55 am ET
Avinger Announces Successful Treatment of First Patients Globally with Pantheris SV, a New Image-Guided Atherectomy Device Designed to Treat Smaller Vessels
REDWOOD CITY, CA / ACCESSWIRE / November 15, 2018 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today announced the successful treatment of the first nine patients with Pantheris SV (Small Vessel) at two separate hospitals in Germany.
Nov 13, 2018 04:01 pm ET
Avinger Provides Third Quarter 2018 Shareholder Update
REDWOOD CITY, CA / ACCESSWIRE / November 13, 2018 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today reported results for the third quarter ended September 30, 2018.
Nov 07, 2018 08:45 am ET
Avinger to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum 2018
REDWOOD CITY, CA / ACCESSWIRE / November 7, 2018 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today announced its participation at the Canaccord Genuity Medical Technologies & Diagnostics Forum 2018. The conference is being held on Thursday, November 15, 2018 at the Westin Grand Central Hotel in New York City.
Nov 05, 2018 07:30 am ET
Avinger to Announce Third Quarter 2018 Financial Results on November 13, 2018
REDWOOD CITY, CA / ACCESSWIRE / November 5, 2018 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today announced that it will release its financial results for the third quarter 2018 after the close of trading on Tuesday, November 13, 2018. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET.
Oct 30, 2018 08:30 am ET
Avinger Announces Pricing of $10 Million Underwritten Public Offering
REDWOOD CITY, CA / ACCESSWIRE / October 30, 2018 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today announced the pricing of an underwritten public offering for gross proceeds of approximately $10 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Avinger.
Oct 18, 2018 08:30 am ET
Avinger Receives CE Marking Approval for Pantheris SV, a New Image-Guided Atherectomy Device Designed to Treat Smaller Vessels
REDWOOD CITY, CA / ACCESSWIRE / October 18, 2018 / Avinger, Inc. (NASDAQ: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced Conformité Européenne (CE) Marking approval of Pantheris SV (Small Vessel), a product line extension of the Lumivascular atherectomy system. CE Marking allows for distribution of Pantheris SV in the European Union (EU) and certain other countries that recognize the CE Marking. Pantheris SV is not available commercially in the United States at this time.
Sep 05, 2018 08:30 am ET
Avinger Announces Successful Treatment of 200th Patient with Next-Generation Pantheris Device
REDWOOD CITY, CA / ACCESSWIRE / September 5, 2018 / Avinger, Inc. (NASDAQ: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that physicians in 35 sites globally have successfully treated over 200 patients with the next-generation Pantheris image-guided atherectomy system for the treatment of peripheral artery disease (PAD).
Aug 30, 2018 08:30 am ET
Avinger Announces 510(k) Filing of Pantheris Small Vessel Device
Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the Company submitted a new 510(k) application to the U.S Food Drug Administration (FDA) for the Pantheris SV (Small...
Aug 29, 2018 08:30 am ET
Avinger Receives New Patent Covering Pantheris Image-Guided Atherectomy System
Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the issuance of an important new patent covering the Company’s Pantheris image-guided atherectomy system. The U.S....
Aug 28, 2018 08:30 am ET
Avinger Announces Participation in Upcoming Investor Conferences
Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that management of Avinger will present at the following investor conferences: Rodman Renshaw 20th Annual Global...
Aug 23, 2018 08:30 am ET
Avinger Completes Enrollment in SCAN Clinical Study
Avinger, Inc. (NASDAQ: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it has completed enrollment in the SCAN clinical study, a post-market study comparing optical coherence tomography...
Aug 13, 2018 04:00 pm ET
Avinger Announces Second Quarter 2018 Financial Results
Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the second quarter ended June 30, 2018. Second Quarter and Recent Highlights Revenue of $2.1 million for...
Aug 06, 2018 10:30 am ET
Avinger to Report Second Quarter 2018 Results on Monday, August 13, 2018
Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), will announce its second quarter 2018 results for the period ended June 30, 2018 on Monday, August 13, 2018 after market close. A...
Jul 12, 2018 08:30 am ET
Avinger Announces Pricing of $3.55 Million Registered Direct Offering
Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase...
Jul 10, 2018 08:30 am ET
Avinger Appoints Jaafer Golzar, MD, FACC, FSCAI, as Chief Medical Officer
Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the appointment, effective immediately, of Jaafer Golzar, MD, as the Company’s Chief Medical Officer. Dr. Golzar provides...
Jun 26, 2018 08:30 am ET
Avinger Announces Successful Treatment of First Patients with Next-Generation Pantheris in Several Centers throughout the US
Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that several physicians have successfully treated over 40 patients in the US across 13 sites with the next-generation...
Jun 21, 2018 08:30 am ET
Avinger’s Ocelot Technology Featured in Live Case Transmission at Complex Cardiovascular Catheter Therapeutics (C3) 2018
Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that its Ocelot image-guided chronic total occlusion (CTO) crossing device was featured in a live case on June 19th at...
Jun 14, 2018 08:30 am ET
Avinger Announces First Patients Enrolled in Post-Market Study Comparing Pantheris OCT Imaging to Intravascular Ultrasound
Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the initiation of the SCAN study, a post-market study comparing optical coherence tomography (OCT) with intravascular...
Jun 13, 2018 08:30 am ET
Avinger Appoints Mark Weinswig as Chief Financial Officer
Avinger, Inc. (NASDAQ:AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that Mark Weinswig will join the Company, and serve in the role of Chief Financial Officer...
May 30, 2018 08:30 am ET
Avinger Announces Presentations and Posters Featuring Lumivascular Technology at New Cardiovascular Horizons Annual Conference
Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced a schedule of sessions and posters highlighting the company’s Lumivascular technology at the New Cardiovascular Horizons...
May 29, 2018 08:30 am ET
Avinger to Present at the 8th Annual LD Micro Invitational
Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that it will be presenting at the 8th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Bel Air,...
May 24, 2018 09:31 am ET
Should you buy stock in Apple, Advanced Micro Devices, Avinger, Best Buy Inc. or Williams-Sonoma?
CHICAGO, May 24, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, AMD, AVGR, BBY, and WSM.
May 23, 2018 08:30 am ET
Avinger Receives FDA Clearance of Next Generation Pantheris Device
Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the Company received 510(k) clearance from the U.S. Food Drug Administration (FDA) for its next generation...
May 14, 2018 04:15 pm ET
Avinger Announces First Quarter 2018 Financial Results
Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the first quarter ended March 31, 2018. First Quarter and Recent Highlights Revenue of $1.8 million for...
May 04, 2018 08:00 am ET
Avinger to Announce First Quarter 2018 Financial Results on May 14, 2018
Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the first quarter 2018 after the close of trading on Monday, May 14, 2018....
Apr 30, 2018 08:30 am ET
Avinger’s Next Generation Pantheris Featured in Live Case Transmission at Charing Cross International Symposium 2018
Charing Cross Symposium (CX) is the longest running vascular and endovascular symposium in Europe and one of the largest in the world
Mar 29, 2018 09:00 am ET
Avinger Announces First-in-Patient use of Extended Nosecone Version of Next Generation Pantheris
Three patients successfully treated using next generation image-guided atherectomy device with enhanced tissue removal capacity for treatment of peripheral artery disease
Mar 21, 2018 08:00 am ET
Avinger Enters into Settlement Agreement for All Outstanding Securities Class Action Litigation
REDWOOD CITY, Calif., March 21, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it has entered into a binding memorandum of...
Mar 19, 2018 04:01 pm ET
Avinger Announces Fourth Quarter and Full Year 2017 Results
REDWOOD CITY, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the fourth quarter and full year ended...
Mar 13, 2018 08:00 am ET
Avinger Provides Update on U.S. Intellectual Property Portfolio
Three New Patents Allowed or Issued for Proprietary CTO Crossing Devices
Mar 06, 2018 08:00 am ET
Avinger to Announce Fourth Quarter 2017 and Full Year 2017 Results on March 19th, 2018
REDWOOD CITY, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the fourth quarter and full...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.